MEDICAL NEWS SITES

OncLive

Lung Cancer | Specialty | OncLive


The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.


Read more

BioSpace

OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011


Milestone as part of the collaborative program named EFFIMab marks continued clinical progress Interleukin-7 receptor antagonist (IL-7R) OSE-127/S95011 is currently in a Phase 2 clinical trial in ulcerative colitis, sponsored by OSE NANTES, France, Jan. 25, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced it received a milestone payment of €1.3 million from Bpifrance related to the Company’s collaborative program, EFFIMab, focused on evaluating interleukin-7 receptor antagonist OSE-127/S95011, partnered with Servier1. This new milestone payment of €1.3 million was triggered by achieving several key steps in the development of OSE-127/S95011 including reinforcement of preclinical and tr...


Read more

OncLive

Jessica Hergert | OncLive


Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.


Read more

NEWS SITES

0c10.jpg?1

Mainichi Shimbun

Hospital beds occupied by 'hidden serious' COVID-19 patients in west Japan


HIMEJI, Hyogo -- Local medical institutions in Japan are on edge amid the new coronavirus pandemic. At the National Hospital Organization Himeji Medical Center, a hospital in this western Japan city that accepts COVID-19 patients with mild to moderate symptoms, beds designated for such patients have been continually occupied since December 2020. One reason for this is that even patients with serious symptoms cannot be transferred to another hospital designated for patients like them if they do not consent to receiving certain treatments including using an artificial respirator. The Mainichi Shumbun interviewed the hospital's assistant director, Tetsuji Kawamura, 59, who said, "I would like to share the sense of crisis we have with people....


Read more

photo.jpg

Times of India

Larry King, broadcasting giant for half-century, dies at 87 - Times of India


LOS ANGELES: Larry King, the suspenders-sporting everyman whose broadcast interviews with world leaders, movie stars and ordinary Joes helped define American conversation for a half-century, died Saturday. He was 87.King died at Cedars-Sinai Medical Center in Los Angeles, Ora Media, the studio and network he co-founded, tweeted. No cause of death was given, but CNN had earlier reported he was hospitalized with COVID-19.A longtime nationally syndicated radio host, from 1985 through 2010 he was a nightly fixture on CNN, where he won many honors, including two Peabody awards.With his celebrity interviews, political debates and topical discussions, King wasn't just an enduring on-air personality.


Read more

NYT-BestSeller-1200x675-699eb842421d5076f318fe0df3d903a5.png

New York Times

Health Books - Best Sellers - Books - The New York Times


A memoir by a physician who received a diagnosis of Stage IV lung cancer at the age of 36.


Read more

JOURNALS

favicon.ico

Dove Press

CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC | IJN


Lung cancer has emerged as the leading cause of cancer-associated deaths worldwide, accounting for about 20% of all cancer deaths.1 In 2018, approximately 2.09 million new lung cancer cases took place, ranking first in all cancer types.2,3 In China, lung cancer mortality is higher than in most other countries, and it is estimated that lung cancer mortality may surge nearly 40% between 2015 and 2030.4 As the primary type of lung cancer, non-small cell lung cancer (NSCLC) exhibits multiple histological types, such as bronchoalveolar carcinoma, large cell carcinoma, squamous cell carcinoma, and adenocarcinoma.5 To date, platinum-based chemotherapy is the most effective therapy to treat advanced NSCLC patients,6 with a significantly higher surv...


Read more

favicon.ico

Dove Press

Role of Antizyme Inhibitor Proteins in Cancers and Beyond


Reprogramming of the metabolic landscape is a hallmark of cancer cells.1 Transformed cells modulate metabolic pathways and nutrient uptake using various adaptation mechanisms to support tumor progression.2 In this regard, the polyamine metabolism is a central pathway hijacked by cancer cells.3,4 Polyamines are small aliphatic polycations biosynthesized from amino acids such as methionine and ornithine and are tightly regulated by de novo synthesis and diet.5 Polyamines play a crucial role in key cellular processes such as cell growth, cell proliferation, apoptosis, and gene regulation.6,7 Notably, polyamine levels are frequently dysregulated in multiple cancer types.3,4 Besides malignant transformation, elevated polyamines are essential for...


Read more

favicon.ico

Dove Press

Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to | CMAR


Dickkopf-1(Dkk1), a typical secretory antagonist of Wnt signaling pathway, was discovered in 1998. Dkk1 is a secretory glycoprotein with two conserved domains rich in cysteine and a connecting region of 50–55 amino acids. The full length of human Dkk1 gene is 1815kb, which is located on chromosome 10q11.2.26. The Dkk1 protein consists of 266 amino acids and its relative molecular weight is about 29 kDa. Dkk2, Dkk3 and Dkk4 have sequence homology in vertebrates, in which Dkk2 and Dkk4 can inhibit Wnt signal, but the inhibitory effect is weaker than Dkk1, and the mechanism of Dkk3 is still unclear.1–4 Wnt signal pathway includes the classical pathway (Wnt/β-catenin) and the non-classical pathway.5,6 In the classical pathway, the activity of ...


Read more

favicon.ico

Dove Press

LncRNA PRNCR1 rs1456315 and CCAT2 rs6983267 Polymorphisms on 8q24 Asso | IJGM


Wei-Ling Yu,1,2,* Jin-Jian Yao,2,3,* Zong-Zhou Xie,1 Yan-Jing Huang,4 Sha Xiao5 1Oncology Department of Haikou City People’s Hospital, Haikou 570208, Hainan, People’s Republic of China; 2Key Laboratory of Emergency and Trauma, Ministry of Education of Hainan Medical University, Haikou 571199, Hainan, People’s Republic of China; 3Emergency Center of Hainan General Hospital Affiliated to Hainan Medical University, Haikou 570311, Hainan, People’s Republic of China; 4Oncology Department of Hainan General Hospital Affiliated to Hainan Medical University, Haikou 570311, Hainan, People’s Republic of China; 5School of Public Health of Hainan Medical University, Haikou 571199, Hainan, People’s Republic of China *These authors contributed equa...


Read more

favicon.ico

Dove Press

Circular RNA CircCDYL Regulates Proliferation and Apoptosis in Non-Sma | CMAR


Wei-Xin Bian,1 Feng Xue,2 Li-Yan Wang,1 Xiao-Fang Xing1 1Department of Oncology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang Province 150001, People’s Republic of China; 2Department of Oncology, Affiliated Hospital of Guilin Medical College, Guilin, Guangxi Province 541001, People’s Republic of China Correspondence: Wei-Xin Bian Department of Oncology, Heilongjiang Provincial Hospital, Harbin, Heilongjiang Province 150001, People’s Republic of China Email pingjuyi3387@126.com Aim: A series of research reveal that circular RNA (circRNA) plays a vital role in regulating the development of tumor cells.


Read more

Cancer Discovery


Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Javier Pascual * Joline S.J. Lim * Iain R. Macpherson * Anne C. Armstrong * Alistair Ring * Alicia F.C. Okines * Rosalind J. Cutts * Maria Teresa Herrera-Abreu * Isaac Garcia-Murillas * Alex Pearson * Sarah Hrebien * Heidrun Gevensleben * Paula Z. Proszek * Michael Hubank * Margaret Hills * Jenny King * Mona Parmar * Toby Prout * Laura Finneran * Jason Malia * Karen E.


Read more

10147.jpg

Springer

The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study


In our single-center study, we evaluated the status of cancer patients infected with COVID-19 at Bakirkoy Dr Sadi Konuk Training and Research Hospital, one of the largest pandemic hospitals in Istanbul. The mortality rate is 1.51% in COVID-19 patient population in our hospital. As expected, the mortality in cancer patients is dramatically higher when compared to the non-cancer population and this rate is 23.9%. It is similar to the analysis of cancer patients in Wuhan, China. In the current study, the mortality rate was slightly higher than ours, with 28.6% [5].


Read more

SOCIAL MEDIA

ProfilePicture.png

Twitter

EMJ Reviews NSCLC, Oncology, Lungcancer, Cancercare: 24/01/2021 10:30:07


Read this interview with four key opinion leaders to learn more about the expanding possibilities in EGFR-mutated advanced NSCLC. https://t.co/Clmc8HgMCO #NSCLC #Oncology #Lungcancer #Cancercare


Read more

ProfilePicture.png

Twitter

EMJ Oncology NSCLC, Oncology, Lungcancer, Cancercare: 24/01/2021 11:00:19


Read this interview with four key opinion leaders to learn more about the expanding possibilities in EGFR-mutated advanced NSCLC. https://t.co/4CoUz5t7vM #NSCLC #Oncology #Lungcancer #Cancercare


Read more

ProfilePicture.png

Twitter

OncLive SOSS lcsm: 24/01/2021 17:01:22


Timothy F. Burns, MD, of @UPMCHillmanCC, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space #lcsm https://t.co/tl4DvOwVBU


Read more

ProfilePicture.png

Twitter

Zonic : 24/01/2021 18:02:32


Bio catalysts ahead; 🤔✍️ $SPPI - Poziotinib - Zenith20 Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2 - Phase 2- Updated Cohort 1 and 2 data to be presented at IASLC meeting January 30, 2021 a...


Read more